Identification of the thistle milk component Silibinin(A) and Glutathione-disulphide as potential inhibitors of the pancreatic lipase: Potential implications on weight loss
MetadataShow full item record
Pancreatic lipaseSilibinin(A)ObesityLipolysisEmulsionInterfacial tension
T. Del Castillo-Santaella et al. Identification of the thistle milk component Silibinin(A) and Glutathione-disulphide as potential inhibitors of the pancreatic lipase: Potential implications on weight loss. Journal of Functional Foods 83 (2021) 104479[https://doi.org/10.1016/j.jff.2021.104479]
SponsorshipSpanish Government RTI2018-101309-B-C21; Fundacion Seneca 20988/PI/18; Ministerio de Economia y Competitividad de Espana CTQ2017-87974-R; Supercomputing infrastructure of Poznan Supercomputing Centre; Einfrastructure program of the Research Council of Norway; Supercomputer centre of UiTthe Arctic University of Norway; Supercomputer centre of UiTthe Arctic University of Norway
Peripheral targets like pancreatic-lipase appear to be the most suitable pharmacological alternative for obesity, as with orlistat, although its adverse effects limit its use. Therefore, the aim of this work was to identify new natural compounds able to inhibit pancreatic-lipase in an in vitro model. The DrugBank database was used to perform docking calculations. The best fitting-score compounds were further evaluated in vitro. Our data revealed that glutathione-disulphide (GSSG) and silibinin(A) inhibit pancreatic-lipase. This was confirmed by measuring hydrolysis in an emulsion model, obtaining that the suppression of lipid digestion by silibinin(A) was higher than that of GSSG and close to the effect of orlistat. Combined analysis established the existence of different inhibition mechanisms for each compound. In summary, silibinin(A) and GSSG inhibited pancreatic-lipase and, therefore, may be served as promise natural compounds to face with obesity. Further studies comprise the next step to fully validate the suitability of these compounds.